241 related articles for article (PubMed ID: 15640822)
1. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.
Gupta S; Zhou P; Hassoun H; Kewalramani T; Reich L; Costello S; Drake L; Klimek V; Dhodapkar M; Teruya-Feldstein J; Hedvat C; Kalakonda N; Fleisher M; Filippa D; Qin J; Nimer SD; Comenzo RL
Bone Marrow Transplant; 2005 Mar; 35(5):441-7. PubMed ID: 15640822
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
3. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
[TBL] [Abstract][Full Text] [Related]
5. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
Bilgrami S; Bona RD; Edwards RL; Li Z; Naqvi B; Shaikh A; Furlong F; Fox J; Clive J; Tutschka PJ
Bone Marrow Transplant; 2001 Jul; 28(2):137-43. PubMed ID: 11509931
[TBL] [Abstract][Full Text] [Related]
6. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.
Lerro KA; Medoff E; Wu Y; Seropian SE; Snyder E; Krause D; Cooper DL
Bone Marrow Transplant; 2003 Dec; 32(12):1113-7. PubMed ID: 14647264
[TBL] [Abstract][Full Text] [Related]
7. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.
Wuchter P; Ran D; Bruckner T; Schmitt T; Witzens-Harig M; Neben K; Goldschmidt H; Ho AD
Biol Blood Marrow Transplant; 2010 Apr; 16(4):490-9. PubMed ID: 19925876
[TBL] [Abstract][Full Text] [Related]
8. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ
Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
[TBL] [Abstract][Full Text] [Related]
9. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Hart C; Grassinger J; Andreesen R; Hennemann B
Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
[TBL] [Abstract][Full Text] [Related]
10. Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity.
Li B; Yang JL; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang S; Zhang CG
Cytotherapy; 2009; 11(3):362-71. PubMed ID: 19037766
[TBL] [Abstract][Full Text] [Related]
11. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity.
Gojo I; Guo C; Sarkodee-Adoo C; Meisenberg B; Fassas A; Rapoport AP; Cottler-Fox M; Heyman M; Takebe N; Tricot G
Bone Marrow Transplant; 2004 Jul; 34(1):69-76. PubMed ID: 15133484
[TBL] [Abstract][Full Text] [Related]
12. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective.
Bargetzi MJ; Passweg J; Baertschi E; Schoenenberger A; Gwerder C; Tichelli A; Burger J; Mingrone W; Herrmann R; Gratwohl A; Wernli M
Bone Marrow Transplant; 2003 Jan; 31(2):99-103. PubMed ID: 12621490
[TBL] [Abstract][Full Text] [Related]
13. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
15. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
17. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
[TBL] [Abstract][Full Text] [Related]
20. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma.
Annunziata M; Celentano M; Pocali B; D'Amico MR; Palmieri S; Viola A; Copia C; Falco C; Del Vecchio L; Ferrara F
Ann Hematol; 2006 Jun; 85(6):394-9. PubMed ID: 16538502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]